Lirentelimab safely improved severe allergy conjunctivitis and concomitant atopic symptoms, according to a study published in The Journal of Allergy and Clinical Immunology.
Stephen D. Anesi, MD, FACS, an associate partner at Massachusetts Eye Research & Surgery Institution, and colleagues noted that ocular allergy is estimated to affect at least 20% and up to 40% of the U.S. population.
“Physicians may resort to systemic corticosteroids for patients with chronic and aggressive symptoms, but its use is associated with adverse effects, especially with long-term use,” Anesi and